Earnings call transcript: Harmony Biosciences misses Q3 2026 profit view

Harmony Biosciences reported Q3 2026 EPS of $0.81, 27% below the $1.11 consensus, while revenue of $268.9 million missed forecasts by 2.05% but rose 12.6% year over year. Higher royalties and a $25 million milestone charge pressured margins and profit; shares fell 8.23% to $33.97 in premarket trading. The company reiterated full-year WAKIX revenue guidance of $1.0 billion-$1.04 billion and reported more than $1 billion in cash, equivalents and investments.

Analysis

The selloff is treating an earnings miss as a single signal, but the components point in different directions. The MSN milestone is a discrete expense; the higher Bioprojet royalty is a recurring margin reset. If investors model the quarter’s cost of sales as temporary, they risk underestimating the earnings drag even with continued WAKIX demand. Conversely, extrapolating the full EPS miss may overstate deterioration if milestone spending does not recur at this level.

The key asymmetry is that commercial execution is currently more verifiable than the proposed offsets to single-product risk. Management’s claimed differentiation versus Takeda’s ORZEYFUL should be tested against post-launch prescribing and patient additions, not accepted as proof of insulation. BP-205 data are still healthy-volunteer safety/PK data; target-engagement effects do not establish a therapeutic window or patient efficacy. Pipeline value should therefore remain heavily discounted until the 1Q27 sleep-deprived study.

Near term, the January 26 preliminary-injunction hearing and expected February 2027 decisions create a binary overhang: an adverse outcome could accelerate generic-risk repricing ahead of the asserted March 2030 exclusivity date. Over 6–18 months, new formulations and pipeline assets may diversify revenue, but clinical and execution risk is substantial. The cash balance limits financing risk, while also creating capital-allocation risk under the incoming CEO. The contrarian case is that the reaction may over-penalize a one-time milestone; the counterpoint is that recurring royalties make normalized margins less attractive than the headline sales growth suggests.

Key Decisions for Investors

• Do not chase the premarket decline. Consider only a small, staged HRMY position after the share price stabilizes and the next report confirms patient additions remain near recent levels; keep sizing modest through the January–February 2027 litigation catalysts. Thesis fails if patient additions materially weaken or guidance is cut.
• Treat the royalty-driven cost-of-sales increase as a higher run-rate until management provides evidence otherwise. Rebuild forward EPS estimates using recurring royalty expense, separating out milestone charges; reduce exposure if gross margin or operating expense trends worsen beyond that reset.
• Use the January 26 preliminary-injunction hearing and expected February decision as explicit event-risk checkpoints, not as a basis to assume management’s exclusivity case will prevail. An adverse ruling or credible at-risk generic launch would invalidate the long thesis and could impair WAKIX economics well before the claimed March 2030 date.
• Keep BP-205 out of near-term valuation support. Reassess only after the 1Q27 study reports patient-relevant wakefulness and tolerability evidence; a favorable safety/PK profile alone is insufficient to underwrite broad CNS upside.